What technology area does this patent fall under?

Primary CPC classification C12N9/0006. Mapped technology areas include Chemistry & Metallurgy.

When was this patent published?

Publication date Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Engineered galactose oxidase variant enzymes

US11466259B2 · US · B2

Patent metadata
Field	Value
Publication number	US-11466259-B2
Application number	US-201916460376-A
Country	US
Kind code	B2
Filing date	Jul 2, 2019
Priority date	Jul 9, 2018
Publication date	Oct 11, 2022
Grant date	Oct 11, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides engineered galactose oxidase (GOase) enzymes, polypeptides having GOase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing GOase enzymes are also provided. The present invention further provides compositions comprising the GOase enzymes and methods of using the engineered GOase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.

First claim

Opening claim text (preview).

We claim: 1. An engineered galactose oxidase comprising a polypeptide sequence having at least 95%, sequence identity to SEQ ID NO: 2, or a functional fragment thereof, wherein said engineered galactose oxidase comprises substitutions in said polypeptide sequence at positions 331, 406, and 465, and wherein said engineered galactose oxidase does not comprise substitutions at positions 11 and 71, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2, and wherein said engineered galactose oxidase comprises production of 2-ethynylglyceraldehyde with increased enantiomeric excess of the R-stereoisomer as compared to wild-type F. graminearium galactose oxidase. 2. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 170, 171, 173, 191, 192, 193, 194, 197, 198, 199, 202, 204, 205, 220, 227, 243, 247, 248, 252, 269, 294, 296, 324, 332, 407, 463, 466, 493, 515, 517, 520, 521, and 522, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2. 3. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 171, 173, 188, 192, 197, 199, 203, 220, 223, 243, 252, 294, 295, 296, 332, 407, 466, 493, 515, 517, 520, and 521, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2. 4. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 171/220/295/296/407, 171/220/296/407/520, 171/220/332/407, 171/220/407, 171/243/296/332, 171/295/332, 171/296/407, 171/332, 171/407, 171/407/520, 173, 192/220/295/296/332/521, 192/220/295/520/521, 192/220/296/332/520, 192/220/407, 192/295/296, 192/295/296/332, 192/295/296/520/521, 192/296, 198/294/296, 198/295, 198/295/296, 204, 220, 220/243, 220/243/295/296/332/407/521, 220/243/295/296/407, 220/243/407, 220/243/407/520/521, 220/252/332/407, 220/295/296, 220/295/296/332, 220/295/296/332/407/520, 220/295/296/332/407/521, 220/295/296/407, 220/295/407/520/521, 220/295/407/521, 220/296, 220/296/332/407, 220/296/332/407/520/521, 220/296/407, 220/407, 220/407/520, 227, 243/295, 243/295/407, 243/515/517, 277/296/407/520/521, 284/295/296, 294/296/407 294/521, 295/296, 295/296/332/407, 295/296/407, 295/296/407/521, 295/296/521, 295/332/407/521, 295/332/520/521, 295/407, 296, 296/332/407/520, 296/332/407/521, 296/407, 296/520/521, 332/407, 332/407/520/521, 332/407/521, 407, 407/520, and 517, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2. 5. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 4, 8, 8/29/92/196/258/426, 8/46/92/279/296/426/549/553/597, 8/56/192/194/460/571/598, 8/56/243/560/598, 8/92/258/363/549/553/567, 8/192/194/243/460/553/560, 8/192/460/560/598, 8/258/363/426/553/597, 16, 16/24/43/56/103/220/295/296/499/549, 16/43/56/103/148/220/295/296/499/549, 16/43/63/103/295/304/499/549, 16/43/63/148/295/499, 16/43/103/148/220/295/426/549, 16/43/148/220/295/499, 16/43/295/296/549, 16/43/426/549, 16/56/63/148/295/296/304/426, 16/56/296, 16/56/426/499, 16/63/103/220/295/426/549, 16/148/220/295/296/304/499, 16/148/220/295/426/499/549, 16/148/220/296/549, 16/148/295/426/549, 16/220/499, 16/295/296/426/499/549, 24, 24/36, 24/36/43/148/319/560/637, 24/36/92/148, 24/36/92/222/560/637, 24/36/92/279/319/363/637, 24/36/148/222/279/560/637, 24/43/92/279/363/560/637, 24/43/92/279/499, 24/43/148/295/560, 24/43/148/363, 24/43/148/560, 24/43/222, 24/92/148/279/363, 24/148/637, 24/637, 29, 29/46/92/196/258/279/363/426/481/567/597, 36, 36/43/92/148/222/279/295/499/560/637, 36/92/148/279/319/363/560/637, 36/92/148/499/637, 36/92/319/363/637, 36/92/560, 36/222/279/319/363/560, 43, 43/56/220/296/426/499/549, 43/56/220/426/549, 43/92/148/222/279/499/560, 43/148/279/295/560, 43/148/549, 43/222/279, 43/295/499, 46, 56, 63, 92, 103, 134, 148, 192/243, 194, 196, 220/295/520, 220/295/521, 220/296/304/426/549, 222, 257, 258, 279, 279/560/637, 295, 296, 304, 319, 363, 363/426/481/553, 426, 499, 549, 553, 560, 567, 597, and 637, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2. 6. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 4/8/56/598, 4/56/192/194/257/571/598, 4/56/194/329/598, 4/194/243/549/598, 8/29/46/196/363/481/549/553, 8/56, 8/56/192/194/243/329, 8/56/192/194/243/329/460/560, 8/56/192/194/243/460/560/598, 8/56/192/243/460, 8/56/192/243/598, 8/56/194/257/460/549/560/598, 8/92/196/258/426/597, 8/92/196/481/597, 8/192/194/243/329/460/560, 8/196/258/279/481/549/553, 8/243/460/560/571/598, 8/257/460/560/598, 8/258/363/426/549, 8/279/363/426/481/549/553, 16/43/63/103/295/296/499, 16/43/103/148/295/426/499/549, 16/43/103/304/499/549, 16/43/148/295/296/304/499/549, 16/43/148/296/426/499, 16/43/295/296/499, 16/56/103/220/295, 16/56/103/220/295/296, 16/56/103/295/549, 16/56/148/295/296/304/426/549, 16/56/220/295, 16/56/220/499/549, 16/56/295, 16/56/295/296/549, 16/56/295/499, 16/56/499/549, 16/63/103/148/426/499/549, 16/63/103/426/499/549, 16/63/148/220/295/296/426/499, 16/63/148/499/549, 16/103, 16/103/148, 16/103/148/220/499, 16/103/148/295/426/499/549, 16/103/220/295, 16/148/220/295/426/499, 16/148/295/426, 16/148/295/549, 16/148/426/549, 16/220/295/296, 16/304/426/499, 16/304/499/549, 24/36/92/279/295/363/499, 24/43/92/148/279/295/319/637, 24/43/92/222/279, 24/43/222/319, 24/43/363/637, 24/92, 24/92/148/279, 24/92/222/279/319/637, 24/222/637, 24/279/319, 29/46/92/196/426/481/549/597, 29/46/481/549/553/597, 29/426/549, 29/549/553, 36/43/222/279/363/560, 36/92/148/222/279/319/363/499/560/637, 36/92/222/637, 36/148/279/319/499, 43/148/222/279/560/637, 43/220/295/549, 56/148/220/295/499, 56/194/243/257/329/460, 56/243, 63/103/148/220/295/549, 63/220/295/304/426/499/549, 63/220/295/304/549, 92, 92/222/279/499/560/637, 92/258/363/426/481/549/597, 103/295/499/549, 148/220/304, 148/222, 148/222/560/637, 148/279/319/499, 194/243/329/460, 194/243/329/560/571/598, 220/295/549, 279/296/481/549/553/567/597, 279/560/637, 295/296/426/549, 295/296/549, 295/499/560/637, 296/363/426/481/549, 319/560, 319/637, and 363/560, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2. 7. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 4/43/46/56/63/279/295/319/567/598, 4/43/46/295/319/549/560, 4/43/46/426/549/560, 4/43/148/196/279/319/363/560, 16, 16/24/29, 16/24/29/92/220/279/597/598, 16/24/29/279/549, 16/24/29/279/637, 16/24/43/92/549, 16/24/43/192/220/279/549, 16/29/36/192/319/549/597/598/637, 16/29/36/279/549, 16/29/43/92/192/319, 16/29/43/192/222/319/549/637, 16/29/43/222/279/549, 16/29/92/192/549/637, 16/29/92/220/222/319/549/598, 16/29/92/279/549, 16/29/92/319/549, 16/29/92/549/637, 16/29/192/220/549, 16/29/192/220/549/597, 16/29/192/222/279/549, 16/29/192/222/637, 16/29/192/549, 16/29/220/222/279/549/637, 16/29/220/222/597/598, 16/29/222/

Assignees

Codexis Inc

Inventors

Classifications

C12P21/02
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
C12N9/0006Primary
acting on CH-OH groups as donors (1.1) · CPC title
C12Y101/03009
Galactose oxidase (1.1.3.9) · CPC title
C12N9/001Primary
acting on the CH-CH group of donors (1.3) · CPC title
C12N15/52
Genes encoding for enzymes or proenzymes · CPC title

Patent family

Related publications grouped by family.

View patent family 69101280

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11466259B2 cover?: The present invention provides engineered galactose oxidase (GOase) enzymes, polypeptides having GOase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing GOase enzymes are also provided. The present invention further provides compositions comprising the GOase enzymes and methods of usin…
Who is the assignee on this patent?: Codexis Inc
What technology area does this patent fall under?: Primary CPC classification C12N9/0006. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?: Publication date Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).